Drug updated on 4/16/2024
| Dosage Form | Inhalation spray (oral: 2.5 mcg) |
| Drug Class | Long-acting beta2-adrenergic agonist (LABA) |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
Summary
- Olodaterol (Striverdi Respimat) is indicated for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
- Seven systematic reviews/meta-analyses provided information on the safety and efficacy of Striverdi Respimat compared to other long-acting β2-agonist/long-acting muscarinic antagonist fixed-dose combinations for COPD.
- Olodaterol showed significantly better rates at preventing moderate or severe exacerbations in stable COPD patients over 52 weeks when compared to most other evaluated medications. It also demonstrated comparable lung function efficacy without significant loss over time.
- A specific investigation into cardiovascular safety showcased an acceptable profile for the olodaterol/tiotropium combination, indicating that it did not significantly modulate the risk of arrhythmia, heart failure, myocardial infarction, and stroke compared to monocomponents.
- In terms of population type considerations, a pooled analysis from four randomized controlled trials demonstrated that tiotropium/olodaterol was more effective in improving lung function, health status, and dyspnea severity in maintenance-naïve COPD patients than tiotropium alone. This supports its use as a first-line maintenance treatment.
- Studies highlighted the importance of patient history, especially regarding exacerbations and cardiovascular conditions, suggesting olodaterol/tiotropium as a potentially safer option for these specific concerns, such as cardiovascular safety.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Striverdi Respimat (olodaterol) prescribing information. | 2021 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Romanian clinical guideline for diagnosis and treatment of COPD. | 2020 | Journal of International Medical Research |